FTC Settlement May Portend Antitrust Scrutiny Of ANDA First-Filer Deals
This article was originally published in The Tan Sheet
The Federal Trade Commission's settlement with Perrigo and Alpharma suggests that deals struck between competing first-to-file generic drug manufacturers may trigger future antitrust scrutiny
You may also be interested in...
David Vladeck's appointment as Federal Trade Commission consumer protection chief could herald tighter enforcement against misleading claims for cosmetics and dietary supplements
David Vladeck's appointment as Federal Trade Commission consumer protection chief could bring tighter enforcement against misleading claims for dietary supplements and other products
A price-fixing suit filed by major retailers against Perrigo and Alpharma is the latest development in a string of legal actions facing the companies